Construction of Bifidobacterium infantis as a live oral vaccine that expresses antigens of the major fimbrial subunit (CfaB) and the B subunit of heat-labile enterotoxin (LTB) from enterotoxigenic Escherichia coli

Ma, Yue; Luo, Yaolin; Xue-ping, Huang; Song, Fangzhou; Liu, Geli

doi:10.1099/mic.0.049932-0

Cited by 30 publications

(38 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…For example, Bifidobacterium infantis strains were recently used to express CFA/I or LTB, and these strains together conferred the most protection to rats following challenge with ETEC (797). Other bacteria, such as Shigella spp.…”

Section: Clinical Considerationsmentioning

confidence: 99%

Recent Advances in Understanding Enteric Pathogenic Escherichia coli

et al. 2013

View full text Add to dashboard Cite

SUMMARY Although Escherichia coli can be an innocuous resident of the gastrointestinal tract, it also has the pathogenic capacity to cause significant diarrheal and extraintestinal diseases. Pathogenic variants of E. coli (pathovars or pathotypes) cause much morbidity and mortality worldwide. Consequently, pathogenic E. coli is widely studied in humans, animals, food, and the environment. While there are many common features that these pathotypes employ to colonize the intestinal mucosa and cause disease, the course, onset, and complications vary significantly. Outbreaks are common in developed and developing countries, and they sometimes have fatal consequences. Many of these pathotypes are a major public health concern as they have low infectious doses and are transmitted through ubiquitous mediums, including food and water. The seriousness of pathogenic E. coli is exemplified by dedicated national and international surveillance programs that monitor and track outbreaks; unfortunately, this surveillance is often lacking in developing countries. While not all pathotypes carry the same public health profile, they all carry an enormous potential to cause disease and continue to present challenges to human health. This comprehensive review highlights recent advances in our understanding of the intestinal pathotypes of E. coli .

show abstract

Section: Clinical Considerationsmentioning

confidence: 99%

Recent Advances in Understanding Enteric Pathogenic Escherichia coli

et al. 2013

View full text Add to dashboard Cite

show abstract

“…infantis and was used for bioluminescent imaging of B. breve and expression of two different antigens of enteropathogenic E. coli in a B. longum subsp. infantis strain (2,9,11,12,43).…”

Section: Plasmidsmentioning

confidence: 99%

“…However, in a number of studies E. coli cytosine deaminase (26,27,53), Salmonella enterica FliC (80), proteins of enterotoxigenic E. coli (43), and endostatin (19,41,86) were expressed without providing a signal for secretion or surface display. Nevertheless, the recombinant bifidobacteria have yielded the desired effects at least partially.…”

Section: Localization Signalsmentioning

confidence: 99%

“…Other bifidobacterial promoters used for constitutive recombinant protein expression in bifidobacteria are P amy , the promoter of the ␣-amylase gene of a B. adolescentis strain (43,52), and the promoter of the 16S rRNA gene (61,76). Promoter sequences of other organisms that have been used successfully for expression in bifidobacteria are P help (12), a synthetic Gram-positive consensus promoter designed for constitutive high-level expression in Listeria monocytogenes (70) and Gram-negative bacteria (69), and the lambda phage promoter P R P L (19,28,41,86).…”

Section: Constitutive Promotersmentioning

confidence: 99%

“…A few studies have been recently performed using recombinant bifidobacterial expression antigens of pathogenic bacteria as live vaccines, and initial results in animals have indicated the potential of this new vaccination strategy (43,80,87).…”

mentioning

confidence: 99%

See 2 more Smart Citations

Accessing the Inaccessible: Molecular Tools for Bifidobacteria

Sun

Baur

Zhurina

et al. 2012

Appl Environ Microbiol

View full text Add to dashboard Cite

ABSTRACTBifidobacteria are an important group of the human intestinal microbiota that have been shown to exert a number of beneficial probiotic effects on the health status of their host. Due to these effects, bifidobacteria have attracted strong interest in health care and food industries for probiotic applications and several species are listed as so-called “generally recognized as safe” (GRAS) microorganisms. Moreover, recent studies have pointed out their potential as an alternative or supplementary strategy in tumor therapy or as live vaccines. In order to study the mechanisms by which these organisms exert their beneficial effects and to generate recombinant strains that can be used as drug delivery vectors or live vaccines, appropriate molecular tools are indispensable. This review provides an overview of the currently available methods and tools to generate recombinant strains of bifidobacteria. The currently used protocols for transformation of bifidobacteria, as well as replicons, selection markers, and determinants of expression, will be summarized. We will further discuss promoters, terminators, and localization signals that have been used for successful generation of expression vectors.

show abstract